Skip to main content
Top
Published in: Italian Journal of Pediatrics 1/2019

Open Access 01-12-2019 | Neuroblastoma | Research

Stage 4 s neuroblastoma: features, management and outcome of 268 cases from the Italian Neuroblastoma Registry

Authors: Bruno De Bernardi, Andrea Di Cataldo, Alberto Garaventa, Paolo Massirio, Elisabetta Viscardi, Marta Giorgia Podda, Aurora Castellano, Paolo D’Angelo, Elisa Tirtei, Fraia Melchionda, Simona Vetrella, Francesco De Leonardis, Carmelita D’Ippolito, Annalisa Tondo, Antonella Nonnis, Giovanni Erminio, Anna Rita Gigliotti, Katia Mazzocco, Riccardo Haupt

Published in: Italian Journal of Pediatrics | Issue 1/2019

Login to get access

Abstract

Background

Infants diagnosed with stage 4 s neuroblastoma commonly experience spontaneous disease regression, with few succumbing without response to therapy. We analyzed a large cohort of such infants enrolled in the Italian Neuroblastoma Registry to detect changes over time in presenting features, treatment and outcome.

Methods

Of 3355 subjects aged 0–18 years with previously untreated neuroblastoma diagnosed between 1979 and 2013, a total of 280 infants (8.3%) had stage 4 s characteristics, 268 of whom were eligible for analyses. Three treatment eras were identified on the basis of based diagnostic and chemotherapy adopted. Group 1 patients received upfront chemotherapy; Group 2 and 3 patients underwent observation in the absence of life-threatening symptoms (LTS), except for Group 3 patients with amplified MYCN gene, who received more aggressive therapy.

Results

The three groups were comparable, with few exceptions. Ten-year overall survival significantly increased from 76.9 to 89.7% and was worse for male gender, age 0–29 days and presence of selected LTS on diagnosis, elevated LDH, and abnormal biologic features. Infants who underwent primary resection ± chemotherapy did significantly better. On multivariate analysis, treatment eras and the association of hepatomegaly to dyspnea were independently associated with worse outcome.

Conclusions

Our data confirm that stage 4 s neuroblastoma is curable in nearly 90% of cases. Hepatomegaly associated to dyspnea was the most important independent risk factor. The cure rate could be further increased through timely identification of patients at risk who might benefit from surgical techniques, such as intra-arterial chemoembolization and/or liver transplantation, which must be carried out in institutions with specific expertise.
Appendix
Available only for authorised users
Literature
1.
go back to reference D’Angio GJ, Evans AE, Koop C. Special pattern of widespread neuroblastoma with a favorable prognosis. Lancet. 1971;1:1046–9.CrossRef D’Angio GJ, Evans AE, Koop C. Special pattern of widespread neuroblastoma with a favorable prognosis. Lancet. 1971;1:1046–9.CrossRef
2.
go back to reference Brodeur GM, Pritchard J, Berthold F, De Bernardi B, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.CrossRef Brodeur GM, Pritchard J, Berthold F, De Bernardi B, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.CrossRef
3.
go back to reference Cohn SL, Pearson ADJ, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The international neuroblastoma risk group (INRG) staging system: an INRG task force report. J Clin Oncol. 2008;27:289–97.CrossRef Cohn SL, Pearson ADJ, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The international neuroblastoma risk group (INRG) staging system: an INRG task force report. J Clin Oncol. 2008;27:289–97.CrossRef
4.
go back to reference Brodeur GM. Spontaneous regression of neuroblastoma. Cell Tissue Res. 2018;372:277–86.CrossRef Brodeur GM. Spontaneous regression of neuroblastoma. Cell Tissue Res. 2018;372:277–86.CrossRef
5.
go back to reference Evans AE, Chatten J, D’Angio GJ, Gerson JM, Robinson J, Schnaufer L. A review of 17 IV-S neuroblastoma patients at the Children’s hospital of Philadelphia. Cancer. 1980;45:833–9.CrossRef Evans AE, Chatten J, D’Angio GJ, Gerson JM, Robinson J, Schnaufer L. A review of 17 IV-S neuroblastoma patients at the Children’s hospital of Philadelphia. Cancer. 1980;45:833–9.CrossRef
6.
go back to reference Stokes SH, Thomas PRM, Perez CA, Vietti TJ. Stage IV-S neuroblastoma: results with definitive therapy. Cancer. 1984;53:2083–6.CrossRef Stokes SH, Thomas PRM, Perez CA, Vietti TJ. Stage IV-S neuroblastoma: results with definitive therapy. Cancer. 1984;53:2083–6.CrossRef
7.
go back to reference Stephenson SR, Cook BA, Mease AD, Ruymann FB. The prognostic significance of age and pattern of metastases in stage IV-S neuroblastoma. Cancer. 1986;58:372–5.CrossRef Stephenson SR, Cook BA, Mease AD, Ruymann FB. The prognostic significance of age and pattern of metastases in stage IV-S neuroblastoma. Cancer. 1986;58:372–5.CrossRef
8.
go back to reference Suarez A, Hartmann O, Vassal G, Giron A, Habrand JL, Valteau D, et al. Treatment of stage IV-S neuroblastoma: a study of 34 cases treated between 1982 and 1987. Med Pediatr Oncol. 1991;19:743–477.CrossRef Suarez A, Hartmann O, Vassal G, Giron A, Habrand JL, Valteau D, et al. Treatment of stage IV-S neuroblastoma: a study of 34 cases treated between 1982 and 1987. Med Pediatr Oncol. 1991;19:743–477.CrossRef
9.
go back to reference De Bernardi B, Pianca C, Boni L, Brisigotti M, Carli M, Bagnulo S, et al. Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Italian cooperative group on neuroblastoma. Cancer. 1992;70:1625–33.CrossRef De Bernardi B, Pianca C, Boni L, Brisigotti M, Carli M, Bagnulo S, et al. Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Italian cooperative group on neuroblastoma. Cancer. 1992;70:1625–33.CrossRef
10.
go back to reference Strother D, Shuster JJ, McWilliams N, Nitschke R, Smith EI, Joshi VJ, et al. Results of pediatric oncology group protocol 8104 for infants with stages D and DS neuroblastoma. J Ped Hematol Oncol. 1995;17:254–9.CrossRef Strother D, Shuster JJ, McWilliams N, Nitschke R, Smith EI, Joshi VJ, et al. Results of pediatric oncology group protocol 8104 for infants with stages D and DS neuroblastoma. J Ped Hematol Oncol. 1995;17:254–9.CrossRef
11.
go back to reference Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi VV, Smith EI, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience. J Clin Oncol. 1998;16:2007–17.CrossRef Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi VV, Smith EI, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience. J Clin Oncol. 1998;16:2007–17.CrossRef
12.
go back to reference Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer group study. J Clin Oncol. 2000;18:477–86.CrossRef Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer group study. J Clin Oncol. 2000;18:477–86.CrossRef
13.
go back to reference Schleiermacher G, Rubie H, Hartmann O, Bergeron C, Chastagner P, Mechinaud F, et al. Neuroblastoma Study Group of the French Society of Paediatric Oncology treatment of stage 4s neuroblastoma – report of 10 years’ experience of the French Society of Paediatric Oncology (SFOP). Br J Cancer. 2003;89:470–6.CrossRef Schleiermacher G, Rubie H, Hartmann O, Bergeron C, Chastagner P, Mechinaud F, et al. Neuroblastoma Study Group of the French Society of Paediatric Oncology treatment of stage 4s neuroblastoma – report of 10 years’ experience of the French Society of Paediatric Oncology (SFOP). Br J Cancer. 2003;89:470–6.CrossRef
14.
go back to reference Taggart DR, London WB, DuBois SG, Monclair TF, Nakagawara A, De Bernardi B, et al. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol. 2011;29:4358–64.CrossRef Taggart DR, London WB, DuBois SG, Monclair TF, Nakagawara A, De Bernardi B, et al. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol. 2011;29:4358–64.CrossRef
15.
go back to reference Hsu LL, Evans AE, D'Angio GJ. Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate. Med Pediatr Oncol. 1996;27:521–8.CrossRef Hsu LL, Evans AE, D'Angio GJ. Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate. Med Pediatr Oncol. 1996;27:521–8.CrossRef
16.
go back to reference Simon T. GPOH guidelines for diagnosis and treatment of patients with neuroblastic tumors. Klin Pädiatr. 2017;229:147–67.CrossRef Simon T. GPOH guidelines for diagnosis and treatment of patients with neuroblastic tumors. Klin Pädiatr. 2017;229:147–67.CrossRef
17.
go back to reference Scaruffi P, Parodi S, Mazzocco K, Defferrari R, Fontana V, Bonassi S, et al. Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization. Mol Diagn. 2004;8:93–100.CrossRef Scaruffi P, Parodi S, Mazzocco K, Defferrari R, Fontana V, Bonassi S, et al. Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization. Mol Diagn. 2004;8:93–100.CrossRef
18.
go back to reference Tonini GP, Verdona G, De Bernardi B, Sansone R, Massimo L, Cornaglia-Ferraris P. N-myc oncogene amplification in a patient with IV-s neuroblastoma. Am J Pediatr Hematol Oncol. 1987;9:8–11.CrossRef Tonini GP, Verdona G, De Bernardi B, Sansone R, Massimo L, Cornaglia-Ferraris P. N-myc oncogene amplification in a patient with IV-s neuroblastoma. Am J Pediatr Hematol Oncol. 1987;9:8–11.CrossRef
19.
go back to reference Brinkschmidt C, Poremba C, Christiansen H, Simon R, Schäfer KL, Terpe HJ, Lampert F, et al. Comparative genomic hybridization and telomerase activity analysis identify 2 biologically different groups of 4s neuroblastomas. Brit J Cancer. 1998;77:2223–9.CrossRef Brinkschmidt C, Poremba C, Christiansen H, Simon R, Schäfer KL, Terpe HJ, Lampert F, et al. Comparative genomic hybridization and telomerase activity analysis identify 2 biologically different groups of 4s neuroblastomas. Brit J Cancer. 1998;77:2223–9.CrossRef
20.
go back to reference Spitz R, Hero B, Simon T, Berthold F. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res. 2006;12:3368–73.CrossRef Spitz R, Hero B, Simon T, Berthold F. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res. 2006;12:3368–73.CrossRef
21.
go back to reference Bénard J, Raguénez G, Kauffmann A, Valent A, Ripoche H, Joulin V, et al. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Mol Oncol. 2008;2:261–71.CrossRef Bénard J, Raguénez G, Kauffmann A, Valent A, Ripoche H, Joulin V, et al. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Mol Oncol. 2008;2:261–71.CrossRef
22.
go back to reference Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, et al. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer. 2012;107:1418–22.CrossRef Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, et al. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer. 2012;107:1418–22.CrossRef
23.
go back to reference Haupt R, Garaventa A, Gambini C, Parodi S, Cangemi G, De Bernardi B, et al. Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian neuroblastoma registry. J Clin Oncol. 2010;28:2331–8.CrossRef Haupt R, Garaventa A, Gambini C, Parodi S, Cangemi G, De Bernardi B, et al. Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian neuroblastoma registry. J Clin Oncol. 2010;28:2331–8.CrossRef
24.
go back to reference Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The international neuroblastoma pathology classification (the Shimada system). Cancer. 1999;86:364–72.CrossRef Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The international neuroblastoma pathology classification (the Shimada system). Cancer. 1999;86:364–72.CrossRef
25.
go back to reference De Bernardi B, Conte M, Mancini A, Donfrancesco A, Alvisi P, Tomà P, et al. Localized resectable neuroblastoma: results of the second study of the Italian cooperative group for neuroblastoma. J Clin Oncol. 1995;3:884–93.CrossRef De Bernardi B, Conte M, Mancini A, Donfrancesco A, Alvisi P, Tomà P, et al. Localized resectable neuroblastoma: results of the second study of the Italian cooperative group for neuroblastoma. J Clin Oncol. 1995;3:884–93.CrossRef
26.
go back to reference Guglielmi M, De Bernardi B, Rizzo A, Federici S, Poglino C, Siracisa F, et al. Resection of primary tumor at diagnosis in stage IV-S neuroblastoma: does it affect the clinical course? J Clin Oncol. 1996;14:1537–44.CrossRef Guglielmi M, De Bernardi B, Rizzo A, Federici S, Poglino C, Siracisa F, et al. Resection of primary tumor at diagnosis in stage IV-S neuroblastoma: does it affect the clinical course? J Clin Oncol. 1996;14:1537–44.CrossRef
27.
go back to reference Cañete A, Gerrard M, Rubie H, Castel V, Di Cataldo A, Munzer C, et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol. 2009;27:1014–9.CrossRef Cañete A, Gerrard M, Rubie H, Castel V, Di Cataldo A, Munzer C, et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol. 2009;27:1014–9.CrossRef
28.
go back to reference Van Noesel MM. Neuroblastoma stage 4s: a multifocal stem-cell disease of the developing neural crest. Lancet Oncol. 2012;13:229–30.CrossRef Van Noesel MM. Neuroblastoma stage 4s: a multifocal stem-cell disease of the developing neural crest. Lancet Oncol. 2012;13:229–30.CrossRef
29.
go back to reference Tonini GP, Boni L, Pession A, Rogers D, Iolascon A, Basso G, et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J Clin Oncol. 1997;15:85–93.CrossRef Tonini GP, Boni L, Pession A, Rogers D, Iolascon A, Basso G, et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J Clin Oncol. 1997;15:85–93.CrossRef
30.
go back to reference Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT, Cohn SL. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblatoma: a report from Children’s oncology group. J Clin Oncol. 2008;26:913–8.CrossRef Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT, Cohn SL. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblatoma: a report from Children’s oncology group. J Clin Oncol. 2008;26:913–8.CrossRef
31.
go back to reference Berthold F, Harms D, Lampert F, Niethammer D, Zieschang G. Risk factors in neuroblastoma of infants. Contrib Oncol. 1990;41:101–17. Berthold F, Harms D, Lampert F, Niethammer D, Zieschang G. Risk factors in neuroblastoma of infants. Contrib Oncol. 1990;41:101–17.
32.
go back to reference Martinez DA, King DR, Ginn-Pease ME, Haase GM, Wiener ES. Resection of the primary tumor is appropriate for children with stage IV-S neuroblastoma: an analysis of 37 patients. J Pediatr Surg. 1992;27:1016–20.CrossRef Martinez DA, King DR, Ginn-Pease ME, Haase GM, Wiener ES. Resection of the primary tumor is appropriate for children with stage IV-S neuroblastoma: an analysis of 37 patients. J Pediatr Surg. 1992;27:1016–20.CrossRef
33.
go back to reference Keene DJ, Minford J, Craigie RJ, Humphrey G, Bruce J. Laparostomy closure in stage 4S neuroblastoma. J Pediatr Surg. 2001;46:1–4.CrossRef Keene DJ, Minford J, Craigie RJ, Humphrey G, Bruce J. Laparostomy closure in stage 4S neuroblastoma. J Pediatr Surg. 2001;46:1–4.CrossRef
34.
go back to reference Roberts S, Creamer K, Shoupe B, Flores Y, Robie D. Unique management of stage 4s neuroblastoma complicated by massive hepatomegaly: case report and review of literature. J Pediatr Hematol Oncol. 2002;24:142–4.CrossRef Roberts S, Creamer K, Shoupe B, Flores Y, Robie D. Unique management of stage 4s neuroblastoma complicated by massive hepatomegaly: case report and review of literature. J Pediatr Hematol Oncol. 2002;24:142–4.CrossRef
35.
go back to reference Weintraub M, Bloom AI, Gross E, Revel-Vilk S, Shahroor S, Koplewitz BZ, et al. Successful treatment of progressive stage 4s hepatic neuroblastoma in a neonate with intra-arterial chemoembolization. Pediatr Blood Cancer. 2004;43:148–51.CrossRef Weintraub M, Bloom AI, Gross E, Revel-Vilk S, Shahroor S, Koplewitz BZ, et al. Successful treatment of progressive stage 4s hepatic neuroblastoma in a neonate with intra-arterial chemoembolization. Pediatr Blood Cancer. 2004;43:148–51.CrossRef
36.
go back to reference Boztug K, Kiely E, Roebuck DJ, Gaze M, Begent J, Brock P, et al. Successful treatment of MYCN amplified, progressive stage 4S neuroblastoma in a neonate with hepatic artery embolization in addition to multimodality treatment. Pediatr Blood Cancer. 2006;46:253–7.CrossRef Boztug K, Kiely E, Roebuck DJ, Gaze M, Begent J, Brock P, et al. Successful treatment of MYCN amplified, progressive stage 4S neuroblastoma in a neonate with hepatic artery embolization in addition to multimodality treatment. Pediatr Blood Cancer. 2006;46:253–7.CrossRef
37.
go back to reference Steele M, Jones NL, Ng V, Kamath B, Avitzur Y, Chami R, et al. Successful liver transplantation in an infant with stage 4S(M) neuroblastoma. Pediatr Blood Cancer. 2013;60:515–7.CrossRef Steele M, Jones NL, Ng V, Kamath B, Avitzur Y, Chami R, et al. Successful liver transplantation in an infant with stage 4S(M) neuroblastoma. Pediatr Blood Cancer. 2013;60:515–7.CrossRef
38.
go back to reference Holsten T, Schuster T, Grabhorn E, Hero B, Fruewald MC. Liver transplantation as a potentially lifesaving measure in neuroblastoma stage 4S. Pediatr Hematol Oncol. 2017;34:17–23.CrossRef Holsten T, Schuster T, Grabhorn E, Hero B, Fruewald MC. Liver transplantation as a potentially lifesaving measure in neuroblastoma stage 4S. Pediatr Hematol Oncol. 2017;34:17–23.CrossRef
39.
go back to reference Weintraub M, Waldman E, Koplewitz B, Bloom AI, Gross E, Freeman AI, et al. A sequential treatment algorithm for infants with stage 4s neuroblastoma and massive hepatomegaly. Pediatr Blood Cancer. 2012;59:182–4.CrossRef Weintraub M, Waldman E, Koplewitz B, Bloom AI, Gross E, Freeman AI, et al. A sequential treatment algorithm for infants with stage 4s neuroblastoma and massive hepatomegaly. Pediatr Blood Cancer. 2012;59:182–4.CrossRef
Metadata
Title
Stage 4 s neuroblastoma: features, management and outcome of 268 cases from the Italian Neuroblastoma Registry
Authors
Bruno De Bernardi
Andrea Di Cataldo
Alberto Garaventa
Paolo Massirio
Elisabetta Viscardi
Marta Giorgia Podda
Aurora Castellano
Paolo D’Angelo
Elisa Tirtei
Fraia Melchionda
Simona Vetrella
Francesco De Leonardis
Carmelita D’Ippolito
Annalisa Tondo
Antonella Nonnis
Giovanni Erminio
Anna Rita Gigliotti
Katia Mazzocco
Riccardo Haupt
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Italian Journal of Pediatrics / Issue 1/2019
Electronic ISSN: 1824-7288
DOI
https://doi.org/10.1186/s13052-018-0599-1

Other articles of this Issue 1/2019

Italian Journal of Pediatrics 1/2019 Go to the issue